| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
2 Istanbul Medipol University, School of Medicine, Department of Medical Pharmacology, Istanbul, Turkey
DOI : 10.23893/1307-2080.APS.05606 Viewed : 15623 - Downloaded : 5114 The aim of this study is to investigate the anti-inflammatory, hypoglycemic activity and median lethal lose (LD50) level of limonene mice and rats.
Lethal dose levels were investigated using the probit analysis method. For the measurement of anti-inflammatory activity, seven separate work groups were established and limonene was administered in three different doses 0.15, 0.30, 0.60 mL/ kg. Indomethacin and etodolac were used as reference anti-inflammatory agents.
For the evaluation of hypoglycemic activity, 6 separate work groups, consisting of healthy and diabetic mice were established and glibenclamide was used as the reference agent.
The LD50 level of limonene was determined to be 2.77 mL/kg. It is determined that all administered dosages of limonene possess anti-inflammatory activity; among these, 0.30 mL/kg was equivalent to indomethacin, and the remaining dosages were equivalent to etodolac. No hypoglycemic activity of limonene was observed in healthy and diabetic mice.
As a consequence, it is concluded that limonene did not show hypoglycemic activity, but possessed a strong anti-inflammatory activity.
Keywords : Limonene, anti-inflammatory activity, hypoglycemic activity, median lethal dose, rats, mice